 In April 2014, Kite Pharma completed a $50 million mezzanine private financing of convertible notes.In May 2014, Kite Pharma filed a registration with the SEC for an initial public offering (IPO) of its common stock.In June 2014, Kite Pharma sold 8,625,000 shares of its common stock in their IPO at $17.00 per share, for gross proceeds of $146.6 million.